<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04540107</url>
  </required_header>
  <id_info>
    <org_study_id>161016</org_study_id>
    <secondary_id>NCI-2019-08761</secondary_id>
    <nct_id>NCT04540107</nct_id>
  </id_info>
  <brief_title>Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma</brief_title>
  <official_title>Metabolic Imaging of Patients With Lower Grade Glioma Using Hyperpolarized 13C Pyruvate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susan Chang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sigma-Aldrich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phillips-Medisize</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic&#xD;
      imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging&#xD;
      and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may&#xD;
      help researchers learn more about practical ways of evaluating and standardizing treatment in&#xD;
      patients with brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety and feasibility of hyperpolarized 13C MR metabolic imaging as a new&#xD;
      and unique tool for making an early assessment of progression and evaluation of response to&#xD;
      therapy in patients with lower grade glioma II. To determine whether changes in levels of&#xD;
      hyperpolarized 13C pyruvate, lactate and bicarbonate may provide early evidence of tumor&#xD;
      progression in patients with lower grade glioma who are being followed with surveillance&#xD;
      scans.&#xD;
&#xD;
      III. To determine whether patients with lower grade glioma who are receiving treatment&#xD;
      exhibit a reduction in levels of hyperpolarized 13C lactate/pyruvate at follow-up compared to&#xD;
      their baseline scan.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 groups.&#xD;
&#xD;
      GROUP I: Patients undergo MR imaging (MRI) and MR spectroscopic imaging (MRSI) scans over 1&#xD;
      hour at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI&#xD;
      schedule set by doctors to monitor patients' care.&#xD;
&#xD;
      GROUP II: Patients undergo MRI scan at baseline. Patients then receive hyperpolarized carbon&#xD;
      C 13 pyruvate intravenously (IV) over less than 1 minute and undergo MRSI scan at baseline.&#xD;
      Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by&#xD;
      doctors to monitor patients' care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events (AEs)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Safety evaluation for endpoint will include monitoring for the occurrence of treatment-emergent adverse events (AEs). Reported toxicities will be graded using the National Cancer Institute (NCI) Common Terminology (Toxicity) Criteria for Adverse Events (CTCAE) version 4.0. All available safety data will be used and will be analyzed using descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak lactate/pyruvate and bicarbonate/pyruvate</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The peak lactate/pyruvate and bicarbonate/pyruvate in tumor and normal appearing brain tissue will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in peak lactate/pyruvate and bicarbonate/pyruvate between scans</measure>
    <time_frame>Baseline up to 4 years</time_frame>
    <description>The change in peak lactate/pyruvate and bicarbonate/pyruvate between scans will be reported.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Recurrent World Health Organization (WHO) Grade II Glioma</condition>
  <condition>Recurrent WHO Grade III Glioma</condition>
  <condition>WHO Grade II Glioma</condition>
  <condition>WHO Grade III Glioma</condition>
  <arm_group>
    <arm_group_label>Group I (MRI, MRSI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo MRI and MRSI scans over 1 hour at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (MRI, hyperpolarized carbon C 13 pyruvate, MRSI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo MRI scan at baseline. Patients then receive hyperpolarized carbon C 13 pyruvate IV over less than 1 minute and undergo MRSI scan at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized Carbon C 13 Pyruvate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group II (MRI, hyperpolarized carbon C 13 pyruvate, MRSI)</arm_group_label>
    <other_name>Hyperpolarized 13C-Pyruvate</other_name>
    <other_name>Hyperpolarized Pyruvate (13C)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo MRI</description>
    <arm_group_label>Group I (MRI, MRSI)</arm_group_label>
    <arm_group_label>Group II (MRI, hyperpolarized carbon C 13 pyruvate, MRSI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Spectroscopic Imaging</intervention_name>
    <description>Undergo MRSI</description>
    <arm_group_label>Group I (MRI, MRSI)</arm_group_label>
    <arm_group_label>Group II (MRI, hyperpolarized carbon C 13 pyruvate, MRSI)</arm_group_label>
    <other_name>1H- Nuclear Magnetic Resonance Spectroscopic Imaging</other_name>
    <other_name>1H-nuclear magnetic resonance spectroscopic imaging</other_name>
    <other_name>Magnetic Resonance Spectroscopy</other_name>
    <other_name>MRS</other_name>
    <other_name>MRS Imaging</other_name>
    <other_name>MRSI</other_name>
    <other_name>Proton Magnetic Resonance Spectroscopic Imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For patients in cohort 1: histologically proven lower grade glioma who are being&#xD;
             followed with surveillance scans&#xD;
&#xD;
          -  For patients in cohort 2: histologically proven glioma who are scheduled for treatment&#xD;
             due to suspected residual or recurrent tumor&#xD;
&#xD;
          -  Patients with a life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Patients must have a Karnofsky performance status of &gt; 60&#xD;
&#xD;
          -  Patients must have adequate renal function (creatinine &lt; 1.5 mg/dL) before starting&#xD;
             therapy. This test must be performed within 60 days prior to the hyperpolarized&#xD;
             imaging scan&#xD;
&#xD;
          -  Patients must not have any significant medical illnesses that in the investigator's&#xD;
             opinion cannot be adequately controlled with appropriate therapy, would compromise the&#xD;
             patient's ability to participate in this study or any disease that will obscure&#xD;
             toxicity or dangerously impact response to the imaging agent&#xD;
&#xD;
          -  Patients must not have New York Heart Association (NYHA) grade II or greater&#xD;
             congestive heart failure&#xD;
&#xD;
          -  Patients must not have history of myocardial infarction or unstable angina within 12&#xD;
             months prior to study enrollment&#xD;
&#xD;
          -  This study was designed to include women and minorities, but was not designed to&#xD;
             measure differences of intervention effects. Males and females will be recruited with&#xD;
             no preference to gender. Minorities will actively be recruited to participate. No&#xD;
             exclusion to this study will be based on race&#xD;
&#xD;
          -  Patients must sign an informed consent indicating that they are aware of the&#xD;
             investigational nature of this study. Patients must sign an authorization for the&#xD;
             release of their protected health information&#xD;
&#xD;
          -  Patients may not be known to be human immunodeficiency virus (HIV)-positive. HIV&#xD;
             testing is not required for study participation&#xD;
&#xD;
          -  Patients must not have a history of any other cancer (except non-melanoma skin cancer&#xD;
             or carcinoma in-situ of the cervix), unless they are in complete remission and have&#xD;
             been off all therapy for that disease for a minimum of 3 years&#xD;
&#xD;
          -  Patients must not be pregnant or breast-feeding. Women of childbearing potential are&#xD;
             required to obtain a negative pregnancy test within 14 days of hyperpolarized imaging&#xD;
             scan. Effective contraception (men and women) must be used in subjects of&#xD;
             child-bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will be excluded from participating in this study if they are unable to&#xD;
             comply with study and/or follow-up procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy Ma</last_name>
    <phone>877-827-3222</phone>
    <email>cancertrials@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Ma</last_name>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Susan M. Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Susan Chang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Hyperpolarized Pyruvate (13C)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

